RAPLIXA

This brand name is authorized in Estonia, Lithuania.

Active ingredients

The drug RAPLIXA contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Human fibrinogen UNII `N94833051K` - FIBRINOGEN HUMAN
	Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (F XIIIa) and calcium ions is converted into a stable and elastic three-dimensional fibrin haemostatic clot. The administration of human fibrinogen concentrate provides an increase in plasma fibrinogen level and can temporarily correct the coagulation defect of patients with fibrinogen deficiency.
	Read more about Human fibrinogen
`2`	Thrombin UNII `6K15ABL77G` - HUMAN THROMBIN
	Read more about Thrombin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BC30	Combinations	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BC Local hemostatics
Discover more medicines within B02BC30

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1680825, 1680836, 1680847
LT	Valstybinė vaistų kontrolės tarnyba	1076030, 1076031, 1076032

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.